Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
“ Imatinib was less effective in HES and CEL without known molecular aberration (n = 15); CHR was observed in 40% (6/15) of patients, two patients relapsed after 4·8 and 24·5 months.”
British journal of haematology • 2008 | View Paper
“Dramatic improvements have been observed in the management of F/P+ CEL with the use of imatinib , a tyrosine kinase inhibitor targeting PDGFRA, but reversibility of EMF remains uncertain.”